Trial Profile
Defibrotide in the prevention of recurrences in venous thrombosis: DEPRIVE. A randomised, multicentre, European, double blind, parallel group study, to assess the efficacy and tolerability of defibrotide versus placebo in the prevention of recurrences in venous thromboembolism.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 31 May 2011
Price :
$35
*
At a glance
- Drugs Defibrotide (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Acronyms DEPRIVE
- 31 May 2011 New trial record